ACRE-IMPACT-CAPITAL
17.4.2024 09:04:29 CEST | Business Wire | Press release
Acre Impact Capital, a private-debt impact investment manager announces the first closing of its Export Finance Fund I (the “Fund”), with commitments of ~US$100mn, with a target size of US$300mn.
The Fund has attracted a diverse group of investors including institutional investors, major Development Finance Institutions (DFIs), family offices and impact-first investors such as Trimtab Impact and Ceniarth. DFIs include the European Investment Bank and FSD Africa Investments. The Fund has also secured significant commitments from several African investors, reflecting the attractive risk-return profile and expected impact of the strategy.
Addressing the urgent need for climate infrastructure investment
Acre Impact Capital’s innovative Export Finance Fund I is the first fund of its kind leveraging the transaction facilitation role of export credit agencies (“ECAs”) for impact. Export finance delivers long-term debt financing guaranteed by official ECAs, allowing project sponsors to significantly reduce the cost of debt by obtaining attractive funding on ECA-backed financing and extending tenors up to 22 years. In doing so, ECAs significantly enhance project affordability and crowd-in private capital.
The Fund addresses a critical financing gap for African climate-aligned infrastructure. While commercial banks typically fund the tranche guaranteed by an ECA (worth 85% of the project value), funding for the remaining 15% commercial debt tranche has been increasingly scarce. By providing specialist funding for this tranche, the Fund will unlock transactions and mobilise $5.6 of private sector capital for each dollar invested.
“We are incredibly proud to have received support from our limited partners, who have backed our pioneering Export Finance Fund I. The current credit environment creates attractive opportunities for discerning investors, while addressing the urgent need for funding for climate-aligned infrastructure projects.” said Hussein Sefian, CEO of Acre Impact Capital. “The Fund aims to invest in 15-20 projects in four thematic areas: (i) Renewable Power; (ii) Health, Food and Water Scarcity; (iii) Sustainable Cities and (iv) Green Transportation. These projects will deliver significant environmental and social impact while providing investors with desirable diversification.”
Commitment to 2X Challenge
The Fund is committed to gender smart investing and seeks to ensure at least 30% of its portfolio of projects meet the 2X Criteria, increasing the number of women represented across its investment portfolio. In addition, Acre Impact Capital commits to promote and maintain gender balance at the fund manager and creating a culture that values diversity and inclusion.
Acre Impact Capital is a recipient of Technical Assistance from United States Agency for International Development (USAID)'s Scaling-Up Renewable Energy (SURE) programme to support the integration of the gender equality and social inclusion in its investment processes.
About Acre Impact Capital
Acre Impact Capital invests in climate-aligned essential infrastructure by partnering with leading commercial lenders and export credit agencies. Acre Impact Capital’s Export Finance Fund I addresses the estimated $100 billion annual infrastructure financing gap in Africa, driving economic growth and providing essential services for underserved populations.
Acre Impact Capital’s development was supported by funding provided by the Private Infrastructure Development Group’s (PIDG) Technical Assistance, through PIDG Company GuarantCo. PIDG is an innovative finance organisation funded by the governments of the UK, the Netherlands, Switzerland, Australia, Sweden, Germany and the IFC. Support for the design and development of the Fund was provided by The Rockefeller Foundation.
Website: https://www.acre.capital/
LinkedIn: https://www.linkedin.com/company/acre-impact-capital
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417910656/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom